Clinical Development and Regulatory Approval Risks: The company's future depends on successful completion of clinical trials and obtaining necessary regulatory approvals (e.g., FDA, CE Mark) for its Sympathetic Tone Assessment (STA) System, which is a lengthy, expensive, and uncertain process that may not yield favorable results or timely approvals.

Commercialization and Market Adoption Risks: Even if regulatory approvals are secured, the company faces significant challenges in achieving market acceptance and widespread adoption of its STA System among healthcare providers, which will be influenced by factors such as physician education, clinical data, competitive landscape, and the availability of adequate reimbursement.

Intellectual Property Protection Risks: The company's success relies heavily on its ability to protect its proprietary technology through patents and other intellectual property rights, and there is no guarantee that its patents will be sufficiently broad, enforceable, or immune to challenges from competitors, which could erode its competitive advantage.